Figure 4.

Targeting postinjury inflammation with h2G7 prolongs the therapeutic window of opportunity compared to NAC treatment. APAP‐challenged C57BL/6J mice (300 mg/kg) were treated (A) 2 or (B) 6 hours post‐APAP with 300 μg of h2G7, 300 μg of E2 control antibody or 500 mg/kg of NAC alone or in combination (n = 10) and sacrificed at 24 hours post‐APAP. Hepatoprotection was recorded as a decrease in serum ALT levels. Data are presented as means ± SEM. ^* P < 0.05; ^** P < 0.01; and ^*** P < 0.001 by Kruskal‐Wallis with Dunn's posttest. Abbreviations: ns, not significant.